TScan Therapeutics (TCRX) Short Interest Ratio & Short Volume $1.61 +0.01 (+0.63%) As of 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TScan Therapeutics Short Interest DataTScan Therapeutics (TCRX) has a short interest of 2.01 million shares, representing 4.59% of the float (the number of shares available for trading by the public). This marks a -12.61% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.5, indicating that it would take 3.5 days of the average trading volume of 413,725 shares to cover all short positions.Current Short Interest2,010,000 sharesPrevious Short Interest2,300,000 sharesChange Vs. Previous Month-12.61%Dollar Volume Sold Short$2.88 millionShort Interest Ratio3.5 Days to CoverLast Record DateMay 31, 2025Outstanding Shares56,591,000 sharesFloat Size43,830,000 sharesShort Percent of Float4.59%Today's Trading Volume253,242 sharesAverage Trading Volume413,725 sharesToday's Volume Vs. Average61% Short Selling TScan Therapeutics? Sign up to receive the latest short interest report for TScan Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartTCRX Short Interest Over TimeTCRX Days to Cover Over TimeTCRX Percentage of Float Shorted Over Time TScan Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/20252,010,000 shares $2.88 million -12.6%4.6%3.5 $1.44 5/15/20252,300,000 shares $3.01 million +28.5%5.3%4.1 $1.31 4/30/20251,790,000 shares $2.87 million -1.7%4.1%3.9 $1.61 4/15/20251,820,000 shares $2.37 million -10.3%4.2%4.1 $1.30 3/31/20252,030,000 shares $2.80 million +6.8%4.7%4.9 $1.38 3/15/20251,900,000 shares $3.31 million -14.8%4.4%4.4 $1.74 2/28/20252,230,000 shares $4.68 million +11.5%5.2%4.8 $2.10 2/15/20252,000,000 shares $4.10 million +9.9%4.9%4.5 $2.05 1/31/20251,820,000 shares $4.68 million -9.0%4.2%4.5 $2.57 1/15/20252,000,000 shares $5.30 million -20.6%4.6%5 $2.65 Get the Latest News and Ratings for TCRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/20242,520,000 shares $7.66 million +7.2%5.8%6.4 $3.04 12/15/20242,350,000 shares $6.70 million +1.3%5.4%7.5 $2.85 11/30/20242,320,000 shares $11.07 million +0.9%5.3%9.4 $4.77 11/15/20242,300,000 shares $10.14 million +6.5%5.3%10.5 $4.41 10/31/20242,160,000 shares $9.81 million -3.6%5.2%9.6 $4.54 10/15/20242,240,000 shares $12.39 million +8.2%5.4%10.7 $5.53 9/30/20242,070,000 shares $10.31 million +15.0%5.0%9.3 $4.98 9/15/20241,800,000 shares $10.33 million +31.4%4.3%5 $5.74 8/31/20241,370,000 shares $7.71 million +9.6%3.3%3.8 $5.63 8/15/20241,250,000 shares $7.24 million +5.9%3.0%3.5 $5.79 7/31/20241,180,000 shares $8.43 million +15.7%2.9%3.3 $7.14 7/15/20241,020,000 shares $7.24 million +67.7%2.5%3 $7.10 6/30/2024608,200 shares $3.56 million +18.7%1.5%1.7 $5.85 6/15/2024512,400 shares $4.30 million +6.1%1.2%2.2 $8.40 5/31/2024482,800 shares $4.13 million +26.5%1.2%2.3 $8.55 5/15/2024381,800 shares $3.41 million -4.1%0.9%1.9 $8.93 4/30/2024398,000 shares $3.07 million -5.2%1.0%1.9 $7.72 4/15/2024419,700 shares $3.23 million +91.3%1.1%2.2 $7.69 3/31/2024219,400 shares $1.74 million +16.5%0.6%1.3 $7.94 3/15/2024188,300 shares $1.34 million +0.3%0.5%1.2 $7.12 2/29/2024187,700 shares $1.27 million -25.8%0.5%1.2 $6.75 2/15/2024252,900 shares $1.45 million +3.8%0.7%1.6 $5.74 1/31/2024243,600 shares $1.24 million -6.4%0.6%1.8 $5.11 1/15/2024260,300 shares $1.56 million -14.6%0.7%2 $6.00 12/31/2023304,700 shares $1.78 million -14.1%0.8%2.3 $5.83 12/15/2023354,700 shares $1.76 million -5.0%0.9%3.1 $4.95 11/30/2023373,300 shares $2.44 million -10.3%1.0%3.1 $6.53 11/15/2023416,000 shares $1.98 million -11.6%1.1%3.5 $4.76 10/31/2023470,700 shares $1.81 million -10.5%1.2%4.4 $3.85 10/15/2023526,000 shares $1.77 million -7.2%1.4%5.1 $3.37Trump’s Exec Order #14154 could be a “Millionaire-Maker” (Ad)Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. For the moment, you can watch this interview free of charge – just click here. 9/30/2023566,900 shares $1.45 million +50.5%1.5%4.7 $2.56 9/15/2023376,800 shares $1.09 million +12.5%1.0%2.9 $2.89 8/31/2023334,800 shares $796.82 thousand -5.0%0.9%2.5 $2.38 8/15/2023352,300 shares $739.83 thousand -9.8%0.9%1.4 $2.10 7/31/2023390,700 shares $875.17 thousand +9.0%0.9%0.3 $2.24 7/15/2023358,400 shares $756.22 thousand -5.6%0.8%0.2 $2.11 6/30/2023379,600 shares $949 thousand -5.6%0.9%0.3 $2.50 6/15/2023401,900 shares $1.09 million -19.6%1.0%0.3 $2.72 5/31/2023499,900 shares $1.15 million +19.8%1.4%0.4 $2.30 5/15/2023417,400 shares $1.68 million +365.9%2.9%0.3 $4.03 4/30/202389,600 shares $203.39 thousand -2.3%0.7%0.1 $2.27 4/15/202391,700 shares $200.82 thousand -24.7%0.7%0.6 $2.19 3/31/2023121,700 shares $255.57 thousand -21.0%0.9%0.8 $2.10 3/15/2023154,000 shares $403.48 thousand -2.0%1.2%1 $2.62 2/28/2023157,100 shares $463.45 thousand +4.0%1.2%1 $2.95 2/15/2023151,000 shares $407.70 thousand -50.3%1.2%1 $2.70 1/31/2023303,800 shares $552.92 thousand +109.7%3.3%2.2 $1.82 1/15/2023144,900 shares $318.78 thousand -1.6%1.6%1.1 $2.20 12/30/2022147,200 shares $228.16 thousand +1.1%1.6%5.8 $1.55 12/15/2022145,600 shares $276.64 thousand -5.9%1.6%7.4 $1.90 11/30/2022154,800 shares $334.37 thousand -3.9%1.7%8.5 $2.16 11/15/2022161,000 shares $431.48 thousand +14.9%1.8%8.5 $2.68 10/31/2022140,100 shares $378.27 thousand +151.5%1.5%7.3 $2.70 10/15/202255,700 shares $167.10 thousand -7.0%0.6%2.6 $3.00 9/30/202259,900 shares $182.70 thousand +12.6%0.7%3 $3.05 9/15/202253,200 shares $173.43 thousand +731.3%0.6%2.5 $3.26 8/31/20226,400 shares $17.60 thousand -96.8%0.1%0.3 $2.75 8/15/2022202,300 shares $681.75 thousand +12.3%2.2%9.9 $3.37 7/31/2022180,200 shares $791.08 thousand +8.8%2.0%1.9 $4.39 7/15/2022165,700 shares $565.04 thousand +5.5%1.8%1.7 $3.41 6/30/2022157,000 shares $493.77 thousand -0.2%1.7%1.5 $3.15 6/15/2022157,300 shares $493.92 thousand +17.0%1.7%1.3 $3.14 5/31/2022134,500 shares $430.40 thousand -41.9%1.5%1.1 $3.20 5/15/2022231,600 shares $576.68 thousand +830.1%2.5%1.9 $2.49 4/30/202224,900 shares $53.54 thousand +11.2%0.3%0.4 $2.15 4/15/202222,400 shares $58.91 thousand +1.8%0.3%0.5 $2.63 3/31/202222,000 shares $61.60 thousand +31.0%0.3%0.5 $2.80 3/15/202216,800 shares $60.65 thousand -35.6%0.2%0.5 $3.61 2/28/202226,100 shares $109.62 thousand -20.7%0.3%0.7 $4.20 2/15/202232,900 shares $177.66 thousand -39.1%0.4%1 $5.40 1/31/202254,000 shares $260.82 thousand -27.8%0.6%1.6 $4.83 1/15/202274,800 shares $377.74 thousand -21.8%0.7%2.2 $5.05 12/31/202195,700 shares $430.65 thousand -2.5%0.9%2.4 $4.50 12/15/202198,100 shares $485.60 thousand +4.0%1.0%2.3 $4.95 11/30/202194,300 shares $722.34 thousand +38.3%0.9%1.6 $7.66 11/15/202168,200 shares $554.47 thousand +32.2%0.7%1 $8.13 10/29/202151,600 shares $452.02 thousand +11.7%0.6%0.6 $8.76 10/15/202146,200 shares $311.85 thousand -50.1%0.5%0.5 $6.75 9/30/202192,500 shares $771.45 thousand +2,102.4%1.0%0.7 $8.34 9/15/20214,200 shares $28.85 thousand -67.4%0.1%0 $6.87Gold is soaring. Here’s how to get paid from it (Ad)Gold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.Click here to discover the income ETF behind it all. 8/31/202112,900 shares $114.68 thousand -16.2%0.1%0.1 $8.89 8/13/202115,400 shares $158.93 thousand No Change0.2%0.1 $10.32 TCRX Short Interest - Frequently Asked Questions What is TScan Therapeutics' current short interest? Short interest is the volume of TScan Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 31st, traders have sold 2,010,000 shares of TCRX short. 4.59% of TScan Therapeutics' shares are currently sold short. Learn More on TScan Therapeutics' current short interest. What is a good short interest ratio for TScan Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TCRX shares currently have a short interest ratio of 4.0. Learn More on TScan Therapeutics's short interest ratio. What is a good short interest percentage for TScan Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.59% of TScan Therapeutics' floating shares are currently sold short. Is TScan Therapeutics' short interest increasing or decreasing? TScan Therapeutics saw a drop in short interest in the month of May. As of May 31st, there was short interest totaling 2,010,000 shares, a drop of 12.6% from the previous total of 2,300,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is TScan Therapeutics' float size? TScan Therapeutics currently has issued a total of 56,591,000 shares. Some of TScan Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. TScan Therapeutics currently has a public float of 43,830,000 shares. How does TScan Therapeutics' short interest compare to its competitors? 4.59% of TScan Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to TScan Therapeutics: Humacyte, Inc. (25.29%), Kamada Ltd. (0.16%), Fulcrum Therapeutics, Inc. (10.98%), iTeos Therapeutics, Inc. (7.91%), Revance Therapeutics, Inc. (4.32%), Checkpoint Therapeutics, Inc. (6.19%), Rezolute, Inc. (8.97%), Vigil Neuroscience, Inc. (1.34%), Solid Biosciences Inc. (14.84%), Compass Therapeutics, Inc. (8.45%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks. What does it mean to sell short TScan Therapeutics stock? Short selling TCRX is an investing strategy that aims to generate trading profit from TScan Therapeutics as its price is falling. TCRX shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against TScan Therapeutics? A short squeeze for TScan Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TCRX, which in turn drives the price of the stock up even further. How often is TScan Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TCRX, twice per month. The most recent reporting period available is May, 31 2025. More Short Interest Resources from MarketBeat Related Companies Humacyte Short Squeeze Kamada Short Squeeze Fulcrum Therapeutics Short Squeeze iTeos Therapeutics Short Squeeze Revance Therapeutics Short Squeeze Checkpoint Therapeutics Short Squeeze Rezolute Short Squeeze Vigil Neuroscience Short Squeeze Solid Biosciences Short Squeeze Compass Therapeutics Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TCRX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TCRX Stock Free TCRX Stock Alerts